Relationships among cortical glutathione levels, brain amyloidosis, and memory in healthy older adults investigated in vivo with 1H-MRS and Pittsburgh compound-B PET

American Journal of Neuroradiology

Volumn 38, Issue 6, 2017, Pages 1130-1137

  Chiang, Gloria C ^a   Mao, X ^a   Kang, G ^a   Chang, E ^a   Pandya, S ^a   Vallabhajosula, S ^a   Isaacson, R ^a   Ravdin, L D ^a   Shungu, D C ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; GLUTATHIONE; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN CORTEX; BRAIN REGION; CINGULATE GYRUS; COGNITION; COHORT ANALYSIS; FEMALE; FRONTAL LOBE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; NON INVASIVE PROCEDURE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; OXIDATIVE STRESS; PARIETAL LOBE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; TEMPORAL LOBE; BRAIN; METABOLISM; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOSIS; ANILINE COMPOUNDS; BRAIN; COHORT STUDIES; FEMALE; GLUTATHIONE; HEALTHY VOLUNTEERS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTON MAGNETIC RESONANCE SPECTROSCOPY; THIAZOLES;

EID: 85020498396     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A5143     Document Type: Article

References (59)

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. http://www.alz.org/facts/. Accessed May 29, 2016
2. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702-16
3. Apelt J, Bigl M, Wunderlich P, et al. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 2004;22:475-84
4. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-67
5. Praticò D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-87
6. Komatsu H, Liu L, Murray IV, et al. A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. Biochim Biophys Acta 2007;1768:1913-22
7. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65:631-41
8. Bonda DJ, Wang X, Lee HG, et al. Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass. Neurosci Bull 2014;30:243-52
9. Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012;1822:625-30
10. Resende R, Moreira PI, Proença T, et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 2008;44:2051-57
11. Zhang C, Rodriguez C, Spaulding J, et al. Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease. J Alzheimers Dis 2012;28:655-66
12. Hensley K, Carney JM, Mattson MP, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:3270-74
13. Smith MA, Casadesus G, Joseph JA, et al. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002;33:1194-99
14. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med 2011;52:1733-40
15. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011;10:819-28
16. Sato N, Morishita R. The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Front Aging Neurosci 2015;7:199
17. Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 2010;107:5949-54
18. Lasa L, Ayuso-Mateos JL, Vázquez-Barquero JL, et al. The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis. J Affect Disord 2000;57:261-65
19. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-97
20. Randolph C, Tierney MC, Mohr E, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-19
21. Karantzoulis S, Novitski J, Gold M, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease. Arch Clin Neuropsychol 2013;28:837-44
22. Saykin AJ, Shen L, Foroud TM, et al; Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement 2010;6:265-73
23. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16
24. Vogt BA, Vogt LJ, Vrana KE, et al. Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp Neurol 1998;153:8-22
25. Murray ME, Przybelski SA, Lesnick TG, et al. Early Alzheimer's disease neuropathology detected by proton MR spectroscopy. J Neurosci 2014;34:16247-55
26. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007;80:S146-52
27. Shungu DC, Weiduschat N, Murrough JW, et al. Increased ventricular lactate in chronic fatigue syndrome, III: relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed 2012;25:1073-87
28. Weiduschat N, Mao X, Hupf J, et al. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett 2014;570:102-07
29. Geramita M, van der Veen JW, Barnett AS, et al. Reproducibility of prefrontal γ-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed 2011;24:1089-98
30. Mullins PG, McGonigle DJ, O'Gorman RL, et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 2014;86:43-52
31. An L, Zhang Y, Thomasson DM, et al. Measurement of glutathione in normal volunteers and stroke patients at 3T using J-difference spectroscopy with minimized subtraction errors. J Magn Reson Imaging 2009;30:263-70
32. Nepravishta R, Sabelli R, Iorio E, et al. Oxidative species and S-glutathionyl conjugates in the apoptosis induction by allyl thiosulfate. FEBS J 2012;279:154-67
33. Shungu DC, Mao X, Gonzales R, et al. Brain γ-aminobutyric acid (GABA) detection in vivo with the J-editing (1) H MRS technique: a comprehensive methodological evaluation of sensitivity enhancement, macromolecule contamination and test-retest reliability. NMR Biomed 2016;29:932-42
34. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143-55
35. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-89
36. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132(pt 5):1310-23
37. Jagust WJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology 2009;73:1193-99
38. Landau SM, Breault C, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70-77
39. Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement 2015; 11:757-71
40. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-53
41. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-25
42. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333-44
43. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry 2009;66:81-87
44. Vittinghoff E, Shiboski S, Glidden D, et al. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. New York: Springer-Science and Business Media; 2005;62:138-39
45. Cohen J. A power primer. Psychol Bull 1992;112:155-59
46. How can I compute effect size in Stata for regression? UCLA: Institute for Digital Research and Education. http://www.ats.ucla.edu/stat/stata/faq/regeffectsize.htm. Accessed December 15, 2016
47. Cohen JW. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988
48. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
49. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease: what physicians know, and what they should know. Arch Neurol 1995;52:1074-79
50. Mandal PK, Saharan S, Tripathi M, et al. Brain glutathione levels - a novel biomarker for mild cognitive impairment and Alzheimer's disease. Biol Psychiatry 2015;78:702-10
51. Gu M, Owen AD, Toffa SE, et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 1998;158:24-29
52. Jain A, Mårtensson J, Stole E, et al. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci U S A 1991;88:1913-17
53. Venkateshappa C, Harish G, Mahadevan A, et al. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimer's disease. Neurochem Res 2012;37:1601-14
54. Gibson GE, Starkov A, Blass JP, et al. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta 2010;1802:122-34
55. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-95
56. Duffy SL, Lagopoulos J, Hickie IB, et al. Glutathione relates to neuropsychological functioning in mild cognitive impairment. Alzheimers Dement 2014;10:67-75
57. Lezak MD, Howieson D, Loring D. Neuropsychological Assessment, 4th ed. Oxford: Oxford University Press; 2004:207-15
58. Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007;64:862-71
59. Wonisch W, Falk A, Sundl I, et al. Oxidative stress increases continuously with BMI and age with unfavourable profiles in males. Aging Male 2012;15:159-65